More patients die if there are fewer nurses available – so the UK must resolve its current shortage.
A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company The post Ardelyx’s ambition to revolutionise kidney treatment...
UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 The post EUSA Pharma hopes IL-6 drug will...
Favorable COVID-19 vaccine developments have revived the hopes of several companies that have seen demand for their products crushed by the unprecedented pandemic. That said, the...
Here's what we still need to find out before we can know when we'll be able to return to our pre-coronavirus ways.
Daily U.S. deaths from Covid-19 surpassed 3,000 for the third time in a week as the country expanded its vaccination program and Congress progressed toward approving...
U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk...
Obstructive sleep apnea is very common and is associated with a variety of serious health issues, such as cardiovascular disease and diabetes. Getting a proper diagnosis...
Researchers show that self-harm was on the rise, even without the added stressors of a pandemic Credit: University of Cincinnati A recent study by a team...
Credit: CERN UK scientists have been awarded funding to develop a robust, low-cost ventilator to help patients in low and middle-income countries suffering from severe respiratory...
A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
Employers could require their workers to get vaccinated against COVID-19 via both workplace policies and existing laws. Neither option, however, is simple or straightforward.
The startup opioid use disorder therapy service Bicycle Health will soon be available to patients in half the country, just three years after its launch in...
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the The post AbbVie begins trials of COVID-19 antibody...
The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 The post ABPI chief exec on the UK...
Credit: BAT / KBP Investigational New Drug application approved by the FDA for COVID-19 candidate vaccine, allowing BAT to progress into a Phase I clinical trial...
Did COVID Murder The Flu? Tyler Durden Tue, 12/15/2020 - 18:25 Despite Dr. Fauci's cries about how all vulnerable Americans should make sure to get their...
Gilead Sciences Inc. decided not to pursue the U.S. Food and Drug Administration’s approval of the company's experimental rheumatoid arthritis treatment, filgotinib, following a meeting with...
Credit: Graphic created by M.E. Newman, Johns Hopkins Medicine, with public domain images. COVID-19 and SARS-CoV-2, the virus behind the disease, have caused health care providers...
Harbour BioMed and Utrecht University licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its clinical program to AbbVie.
Synthetic DNA-encoded monoclonal antibodies make the recipient’s body the production plant Credit: The Wistar Institute PHILADELPHIA — (Dec. 15, 2020) — A team of scientists from...
The Austrian researchers are the first in the world to demonstrate ‘YeiN’, an enzyme that is a suitable biocatalyst for the production of C-nucleosides, the basic...
Barclays has been fined £26 million by the UK’s Financial Conduct Authority (FCA) for failures in how the bank treated their consumer credit customers who fell...
Findings could help hospitals improve emergency department care and follow-up for people aged 50 to 80 Credit: University of Michigan Even before the pandemic, older Americans...
Graeme Duncan from ADVANZ PHARMA explores how successful cross-industry collaboration between pharma and generics companies has helped support The post The critical role of the generics...
Eli Lilly & Co. (LLY) announced a 14.9% hike in its quarterly dividend to $0.85 per share from $0.74. The pharmaceutical company said that the new...
H&M Group announced today that fourth quarter sales fell 10% in local currency (Swedish Krona) terms for the period September 1 to November 30, compared to...
Switzerland’s Roche Holding AG announced that the US Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for its multiple sclerosis (MS) treatment...
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and...
Credit: Marsh et al. After Julia had a minor stroke, she was thankful for receiving rapid treatment and recovering well. But she did notice an unexpected...